Carbylan Therapeutics halts Hydros-TA development, views options including sale

16 April 2016

US biotech Carbylan Therapeutics (Nasdaq: CBYL) said on Friday that it has suspended further clinical development of Hydros-TA, which recently reported disappointing results in Phase III, and that it is actively pursuing a strategic transaction, including a merger or acquisition of the company.

Carbylan has engaged Wedbush PacGrow to act as its strategic financial advisor for this process. The firm’s shares edged 4.1% higher to $0.6687 on the news, but were down 1% at $0.64 by close of trading. The stock has been in decline since June 2015, when it was trading at $9.04 per share.

In conjunction with the plan to pursue a strategic transaction, Carbylan also announced an immediate reduction in its workforce of 14 employees of its current 17 employees in order to preserve capital and further streamline the company’s operations in preparation for a potential strategic transaction.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >